A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Key Inclusion Criteria:

Parts A, B, and C:

- Female subjects must be of non-childbearing potential.

- Between the ages of 18 and 55 years, inclusive.

- Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive, and a total body weight >50 kg

Parts D, E, and F:

- Body weight ≥35 kg.

- Subjects must have an eligible CFTR genotype:

- Parts D and F: Heterozygous for F508del and an MF mutation (F/MF)

- Part E: Homozygous for F508del (F/F)

- FEV1 value ≥40% and ≤90% of predicted mean for age, sex, and height.

Key Exclusion Criteria:

Parts A, B, and C:

- Any condition possibly affecting drug absorption.

- History of febrile illness within 14 days before the first study drug dose.

- Glucose-6-phosphate dehydrogenase (G6PD) deficiency.

Parts D, E, and F:

- History of clinically significant cirrhosis with or without portal hypertension.

- Glucose-6-phosphate dehydrogenase (G6PD) deficiency.

- Lung infection with organisms associated with a more rapid decline in pulmonary
status.

- History of solid organ or hematological transplantation.

Other protocol defined Inclusion/Exclusion criteria may apply.